Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.03 and traded as high as $0.07. Mateon Therapeutics shares last traded at $0.07, with a volume of 76,720 shares.
Mateon Therapeutics Stock Performance
The company has a fifty day simple moving average of $0.04 and a 200-day simple moving average of $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- Transportation Stocks Investing
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Stock Dividend Cuts Happen Are You Ready?
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Using the MarketBeat Dividend Tax Calculator
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
